Best Pract Res Clin Obstet Gynaecol. first vaccination of 18\25\year\old women. Conclusion Sustained anti\HPV\16 and \18 immune responses were observed 8\9 years after AS04\HPV\16/18 vaccination Fluticasone propionate of 9\17 year\old Chinese girls that were higher than Fluticasone propionate the ones observed 6 years after first vaccination in Chinese adult women in whom AS04\HPV\16/18 efficacy against cervical intraepithelial neoplasia of grade 2 was demonstrated. is a trademark owned by or licensed to the GSK group of companies. ACKNOWLEDGMENTS The authors thank all study participants, investigators, nurses, and other staff members for contributing to this study and especially Bndicte Brasseur, Yu He, Jenny Jiang, Ivy Luan, Jazelle Torres, Yuan Xu, and Helen Zhang. The authors thank Business & Decision Life Sciences platform for editorial assistance and manuscript coordination, on behalf of GSK. Bruno Baudoux coordinated the manuscript development and editorial support. Jonathan Ghesquire provided medical writing support. Notes Hu Y, Zhang X, He Y, et?al. Long\term persistence of immune response to the AS04\adjuvanted HPV\16/18 vaccine in Chinese girls aged 9\17 years: Results from an 8\9\year follow\up phase III open\label study. Asia-Pac J Clin Oncol. 2020;16:392C399. 10.1111/ajco.13398 [PMC free article] [PubMed] [CrossRef] [Google Scholar] REFERENCES 1. de Sanjos S, Brotons M, Pavn MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2\13. [PubMed] [Google Scholar] 2. Bruni L, Barrionuevo\Rosas L, Albero G, et?al. em Human Papillomavirus and Related Diseases in the World /em . 2017. Available from: http://hpvcentre.net/statistics/reports/XWX.pdf. Summary Report 27 July. Accessed April 29, 2019. 3. ICO/IARC Info Centre on HPV and Malignancy . em Human being Papillomavirus and Related Diseases Statement China Fluticasone propionate /em . 2018. Available from: https://hpvcentre.net/statistics/reports/CHN.pdf. Utilized May 23, 2019. 4. Joura EA, Giuliano AR, Iversen O\E, et?al. A 9\valent HPV vaccine against illness and intraepithelial neoplasia in ladies. N Engl J Med. 2015;372(8):711\723. [PubMed] [Google Scholar] 5. Kjaer SK, Sigurdsson K, Iversen O\E, et?al. A pooled analysis of continued prophylactic effectiveness of quadrivalent human being papillomavirus (Types 6/11/16/18) vaccine against high\grade cervical and external genital lesions. Malignancy Prev Res. 2009;2(10):868\878. [PubMed] [Google Scholar] 6. Lehtinen M, Paavonen J, Wheeler CM, et?al. Overall effectiveness of HPV\16/18 AS04\adjuvanted vaccine against grade 3 or higher cervical intraepithelial neoplasia: 4\12 months end\of\study analysis of the randomised, double\blind PATRICIA trial. Lancet Oncol. 2012;13(1):89\99. [PubMed] [Google Scholar] 7. Gar?on N, Wettendorff M, Vehicle Mechelen M. Part of AS04 in human being papillomavirus vaccine: mode of action and medical profile. Expert Opin Biol Ther. 2011;11(5):667\677. [PubMed] [Google Scholar] 8. Baldridge JR, McGowan P, Evans JT, et?al. Taking a Toll on human being disease: toll\like receptor 4 agonists as vaccine adjuvants and monotherapeutic providers. Expert Opin Biol Ther. 2004;4(7):1129\1138. [PubMed] [Google Scholar] 9. World Health Business . em Vaccine in National Immunization Programme Upgrade /em . 2019. Available from: http://www.who.int/immunization/monitoring_surveillance/VaccineIntroStatus.pptx. Accessed April 24, 2019. 10. Bruni L, Diaz M, Barrionuevo\Rosas L, et?al. Global estimations of human being papillomavirus vaccination protection by region and income level: a Rabbit Polyclonal to Akt (phospho-Thr308) pooled analysis. Lancet Glob Health. 2016;4(7):e453\e463. [PubMed] [Google Scholar] 11. Harper DM, DeMars LR. HPV vaccines a review of the 1st decade. Gynecol Oncol. 2017;146(1):196\204. [PubMed] [Google Scholar] 12. Palmer T, Wallace L, Pollock KG, et?al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12C13 in Scotland: retrospective populace study. BMJ. 2019;365:l1161. [PMC free article] [PubMed] [Google Scholar] 13. Kavanagh K, Pollock KG, Cuschieri K, et?al. Changes in the prevalence of human being papillomavirus following a national bivalent human being papillomavirus vaccination programme in Scotland: a 7\12 months cross\sectional study. Lancet Infect Dis. 2017;17(12):1293\1302. [PubMed] [Google Scholar] 14. Woestenberg PJ, King AJ, vehicle Benthem BHB, et?al. Bivalent vaccine performance against type\specific HPV positivity: evidence for cross\safety against oncogenic types among Dutch STI medical center site visitors. J Infect Dis. 2018;217(2):213\222. [PMC free article] [PubMed] [Google Scholar] 15. Zhu F\C, Hu S\Y, Hong Y, et?al. Effectiveness, immunogenicity, and security of the HPV\16/18 AS04\adjuvanted vaccine in Chinese ladies aged 18C25 years: event\induced analysis of a randomized controlled trial. Malignancy Med. 2016;6(1):12\25. [PMC free article] [PubMed] [Google Scholar] 16. Einstein MH, Levin MJ, Chatterjee A, et?al. Comparative humoral and cellular immunogenicity and security of human being papillomavirus.